Barrett’s Esophagus Risk Scoring With Multiplex Tissue Imaging

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for detecting the progression of Barrett's esophagus to esophageal adenocarcinoma are limited by inter-observer variation in histologic evaluation and the lack of accurate biomarkers for risk prediction, making it difficult to identify patients at high risk for progression and requiring ineffective surveillance frequencies.

Innovation Solution

A tissue systems pathology approach using multiplexed fluorescence biomarker labeling and digital imaging to quantify genetic, immunologic, and morphologic features, integrating these into a multivariable classifier to determine a prognostic score for risk of progression to high-grade dysplasia or esophageal adenocarcinoma.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If histologic evaluation of esophageal biopsies is used for surveillance, then current practice guidelines can be followed, but inter-observer variation and random sampling limit measurement precision and reliability

Engineering Contradiction:

Improveprecision of dysplasia detectionVSAvoidreliability of risk prediction

Core Design Contradiction:

Measurement precisionVSReliability

Solution Approach 1:

The patent replaces subjective mechanical histologic evaluation with objective digital image analysis. Multiplexed fluorescence biomarker labeling combined with automated image analysis algorithms eliminates inter-observer variation by using computational methods to quantify biomarker expression levels, nuclear morphology, and tissue architecture features, thereby improving measurement precision and reliability of dysplasia detection

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The patent changes from qualitative histologic grading to quantitative measurement of multiple biomarkers. By measuring expression levels of p53, p16, AMACR, and other biomarkers along with morphometric parameters, the system transforms subjective pathology into objective numerical data that can be reliably used for risk stratification and prediction

Inventive Principle:

Principle #35Parameter changes

2Reliability

If traditional biomarkers are evaluated, then some risk prediction capability exists, but no single biomarker or panel has been accurately identified and validated

Engineering Contradiction:

Improveaccuracy of risk predictionVSAvoidcomplexity of biomarker panel

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent segments the complex disease process into multiple measurable components by evaluating separate biomarkers (p53, p16, AMACR, HIF-1α, COX-2) and their interactions. This segmentation allows each biomarker to be independently optimized and validated, then combined through a multivariable classifier to achieve superior overall prediction accuracy compared to any single marker

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent creates a composite diagnostic system that integrates multiple biomarkers with morphologic features and clinical parameters. This composite approach, implemented through a validated multivariable classifier algorithm, achieves high accuracy in predicting progression to HGD/EAC by synergistically combining information from various sources

Inventive Principle:

Principle #40Composite materials

3Loss of time

If endoscopic surveillance with biopsies is performed, then early detection is aimed, but the frequency of surveillance must be determined and cannot be personalized

Engineering Contradiction:

Improvetime for surveillance intervalsVSAvoidpersonalization of surveillance

Core Design Contradiction:

Loss of timeVSAdaptability or versatility

Solution Approach 1:

The patent implements dynamic surveillance scheduling where biopsy frequency is adjusted based on individual patient risk scores. Patients with high-risk features (high risk score) receive more frequent surveillance, while low-risk patients receive less frequent surveillance, making the surveillance protocol adaptive and personalized rather than static and uniform

Inventive Principle:

Principle #15Dynamics

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The approach provides a more accurate method for risk stratification and early detection of Barrett's esophagus progression, enabling personalized surveillance and therapeutic interventions, thereby improving patient management and survival rates.

Implementation Method 1

multiplexed fluorescence biomarker labeling with digital imaging and image analysis to objectively quantify multiple epithelial and stromal biomarkers and morphology

Methodology Applied

Scientific EffectFluorescence: Fluorescence

Data Source

PatentUS12442819B2Methods of predicting progression of Barrett's esophagus

Publication Date: 2025.10.14 CERNOSTICS

AI summary

Embodiments described herein provide methods of determining a risk of progression of Barrett's esophagus in a subject, classifying Barrett's esophagus in a subject, and detecting a field effect associated with malignant transformation of an esophagus of a subject suffering from Barrett's esophagus. The disclosure also provides kits for determining a risk of progression of Barrett's esophagus in a subject and classifying Barrett's esophagus in a subject.